Has Dhanalakshmi Ramasamy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,817 in general payments to Dhanalakshmi Ramasamy, MD across 96 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dhanalakshmi Ramasamy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dhanalakshmi Ramasamy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dhanalakshmi Ramasamy, MD

Child & Adolescent Psychiatry · Bethlehem,, PANPI 1881649192

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.2% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,162 and has fallen 97.9% since, to $25 in 2025.

$1,817in general payments, 2019–2025

Across 96 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Supernus Pharmaceuticals, Inc.$404
Johnson & Johnson$380
Ironshore Pharmaceuticals Inc.$185
Teva Pharmaceuticals USA, Inc.$180
Tris Pharma Inc$117
Sunovion Pharmaceuticals Inc.$91
plus $462 from 11 others

What the payments were for

Food & beverage$1,71394%
Education$1046%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Supernus Pharmaceuticals, Inc.	9	$404
Johnson & Johnson	23	$380
Ironshore Pharmaceuticals Inc.	7	$185
Teva Pharmaceuticals USA, Inc.	6	$180
Tris Pharma Inc	14	$117
Sunovion Pharmaceuticals Inc.	7	$91
Neurocrine Biosciences, Inc.	6	$86
Shire North American Group Inc	6	$76
Neuronetics, Inc.	3	$71
Adlon Therapeutics L.p.	3	$48
Indivior Inc.	2	$35
Vanda Pharmaceuticals Inc.	2	$34
Otsuka America Pharmaceutical, Inc.	2	$31
Validus Pharmaceuticals LLC	2	$27
AbbVie	2	$25
Avanir Pharmaceuticals, Inc.	1	$16
Alkermes, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QELBREE$250
Jornay PM 20mg capsules (Bottle of 100)$125

How this compares

$1,817 in reported general payments places this provider in the 80th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

See all child & adolescent psychiatry providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$6,094

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Methylphenidate ErMethylphenidate Hcl	17	$1,860
Venlafaxine Hcl ErVenlafaxine Hcl	34	$479
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	13	$476
Aripiprazole	26	$356
Lorazepam	29	$216
Clonazepam	19	$152
Alprazolam	13	$151
Trazodone Hcl	13	$47
Escitalopram Oxalate	13	$20
Citalopram HbrCitalopram Hydrobromide	12	$10

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Bethlehem,

Dennis BorczonErie$120K
Suzanne LucotCranberry Township$72K
Dan UdreaWexford$51K
Robert WilsonErie$34K
Craig FeasterState College$18K
Thomas WindPhiladelphia$17K
Laura AdangPhiladelphia$15K
Christoph LamPhiladelphia$13K
Raman BawejaHershey$11K
Jeffrey HermannYork$10K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →